(Q43547497)

24 November 2017

Scar undone: long-term therapy of hepatitis B. (English)

1 reference

24 November 2017

Michele M Tana

1

1 reference

PubMed ID

23234726

24 November 2017

Jay H Hoofnagle

series ordinal

2

1 reference

PubMed ID

23234726

24 November 2017

language of work or name

English

0 references

publication date

10 December 2012

1 reference

24 November 2017

1 reference

24 November 2017

381

1 reference

24 November 2017

9865

1 reference

24 November 2017

433-434

1 reference

Epidemiology of hepatitis B in the United States

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

Treatment of chronic hepatitis B with interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961721-8

7 January 2021

10.1016/S0140-6736(12)61721-8

Identifiers

DOI

1 reference

24 November 2017

1 reference

PubMed ID

23234726